| Title |
Alzheimer’s Disease Can Be Spared by Nonsteroidal Anti-Inflammatory Drugs
|
|---|---|
| Published in |
Journal of Alzheimer's Disease, March 2018
|
| DOI | 10.3233/jad-170706 |
| Pubmed ID | |
| Authors |
Patrick L. McGeer, Jian Ping Guo, Moonhee Lee, Krista Kennedy, Edith G. McGeer |
| Abstract |
Alzheimer's disease (AD) is characterized by deposits of amyloid-β protein (Aβ) in brain which become foci of inflammation. Neurons are destroyed by this inflammatory process, leading to the cognitive deficits which define AD clinical onset. Epidemiological studies indicate that nonsteroidal anti-inflammatory drugs (NSAIDs) can ameliorate this destructive process if they are started well before clinical signs develop. Biomarker studies indicate that the disease process starts at least a decade before cognitive deficits appear. This pre-clinical onset explains the NSAID effect. It also opens a window of opportunity for preventive treatment that can be met with a simple diagnostic test. Salivary levels of Aβ42 may fulfill that need. They can be measured by a simple ELISA test we have developed using commercially available reagents. By this ELISA test, normal controls, who are not at risk for AD, have levels of Aβ42 close to 20 pg/ml. AD cases, as well as high level controls, secrete levels in the range of 40-85 pg/ml. Widespread application of this test by high level controls, followed by NSAID consumption, could substantially reduce the prevalence of AD. |
X Demographics
The data shown below were collected from the profiles of 133 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Thailand | 13 | 10% |
| United States | 4 | 3% |
| United Kingdom | 3 | 2% |
| Japan | 1 | <1% |
| Lao People's Democratic Republic | 1 | <1% |
| Philippines | 1 | <1% |
| Argentina | 1 | <1% |
| Canada | 1 | <1% |
| Morocco | 1 | <1% |
| Other | 0 | 0% |
| Unknown | 107 | 80% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 130 | 98% |
| Scientists | 2 | 2% |
| Practitioners (doctors, other healthcare professionals) | 1 | <1% |
Mendeley readers
The data shown below were compiled from readership statistics for 86 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 86 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 11 | 13% |
| Student > Bachelor | 10 | 12% |
| Researcher | 9 | 10% |
| Other | 8 | 9% |
| Student > Master | 7 | 8% |
| Other | 17 | 20% |
| Unknown | 24 | 28% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 14 | 16% |
| Neuroscience | 12 | 14% |
| Biochemistry, Genetics and Molecular Biology | 10 | 12% |
| Agricultural and Biological Sciences | 6 | 7% |
| Pharmacology, Toxicology and Pharmaceutical Science | 4 | 5% |
| Other | 15 | 17% |
| Unknown | 25 | 29% |
Attention Score in Context
This research output has an Altmetric Attention Score of 250. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 02 November 2018.
All research outputs
#150,725
of 25,718,113 outputs
Outputs from Journal of Alzheimer's Disease
#123
of 7,536 outputs
Outputs of similar age
#3,591
of 352,840 outputs
Outputs of similar age from Journal of Alzheimer's Disease
#6
of 62 outputs
Altmetric has tracked 25,718,113 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 99th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 7,536 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 21.4. This one has done particularly well, scoring higher than 98% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 352,840 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 98% of its contemporaries.
We're also able to compare this research output to 62 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 90% of its contemporaries.